Menu
Search Close

News

Scancell to present latest SCIB1 data at ASCO Annual Meeting

15th May 2014

Scancell Holdings Plc, (AIM:SCLP), the developer of novel immunotherapies for the treatment of cancer, today announces that the latest data from the ongoing Phase 1/2 clinical trial of SCIB1 ImmunoBody® (‘SCIB1’) in patients with Stage III/IV melanoma will be presented in a poster at the 2014 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, May 30-June 3, 2014.

SCIB1 is being developed for the treatment of melanoma and is in Phase 1/2 clinical trials. The trial is an open label, non-randomised study to determine the safety and tolerability of four dose levels of SCIB1 administered intramuscularly using an electroporation device (TDS-IM, manufactured by Ichor Medical Systems, USA). The study will also assess immune effects and anti-tumour activity in patients with melanoma.

An earlier submitted abstract of the poster can be accessed through the ASCO website at: http://abstracts2.asco.org/.

The title, timing and location of the poster presentation is as follows:

Abstract

3061

Title

Phase I trial of ImmunoBody in Melanoma patients

Presenter:

Prof Poulam Patel

Session:

Developmental Therapeutics - Immunotherapy

Day / Date:

Sunday 1 June, 2014

Session Time:

8:00 am to 11:45 am 

Location:

S Hall A2

For Further Information:

Dr Richard Goodfellow, Joint CEO

Professor Lindy Durrant, Joint CEO

Scancell Holdings Plc

Scancell Holdings Plc

+ 44 (0) 20 3727 1000

Camilla Hume/Stephen Keys

Cenkos Securities plc

+ 44 (0) 20 7397 8900

Mo Noonan/Simon Conway

FTI Consulting

+ 44 (0) 20 3727 1000

About Scancell

Scancell is developing novel immunotherapies for the treatment of cancer based on its ImmunoBody® and Moditope® technology platforms. Scancell’s first ImmunoBody®, SCIB1 is being developed for the treatment of melanoma and is being evaluated in a Phase 1/2 clinical trial. Data from the trial demonstrate that SCIB1 produced a melanoma-specific immune response and promising survival trend.

Scancell’s ImmunoBody® vaccines target dendritic cells and stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic Tlymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope® platform could play a major role in the development of safe and effective cancer immunotherapies in the future.

Webcasts, Interviews and Media Coverage

Scancell to begin UK arm of phase II skin cancer trial ‘immediately’

Discussions with US regulators have taken longer than expected, so Scancell will now focus its efforts on completing the UK arm of the trial before re-submitting its US application at a later date

Mon, 19 Aug 2019 06:46:00

Scancell on verge of recruiting patients with advanced melanoma for UK clinical trials

The immunotherapy specialist gave an update on progress for a “busy and productive” half-year.

Mon, 01 Jul 2019 11:19:00